Surgery Partners, Inc. (NASDAQ:SGRY) Given Average Recommendation of “Moderate Buy” by Brokerages

Surgery Partners, Inc. (NASDAQ:SGRY) has earned a consensus recommendation of “Moderate Buy” from the twelve analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $24.4545.

Several equities analysts have issued reports on SGRY shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Surgery Partners in a research report on Monday, December 29th. Cantor Fitzgerald restated an “overweight” rating on shares of Surgery Partners in a report on Wednesday. Barclays lowered their target price on Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating for the company in a research note on Tuesday, March 3rd. Royal Bank Of Canada cut their price target on Surgery Partners from $31.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Mizuho reduced their price target on shares of Surgery Partners from $19.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday.

Surgery Partners Stock Performance

NASDAQ SGRY opened at $13.36 on Monday. Surgery Partners has a 1-year low of $12.25 and a 1-year high of $24.64. The company has a 50 day moving average of $15.20 and a 200-day moving average of $18.07. The company has a current ratio of 1.87, a quick ratio of 1.71 and a debt-to-equity ratio of 1.15. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of -21.55 and a beta of 1.95.

Surgery Partners (NASDAQ:SGRY) last announced its earnings results on Monday, March 2nd. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.19). The business had revenue of $885.00 million during the quarter, compared to analyst estimates of $866.54 million. Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.The firm’s revenue was up 2.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.44 earnings per share. On average, equities analysts forecast that Surgery Partners will post 0.67 earnings per share for the current fiscal year.

Surgery Partners announced that its board has authorized a stock repurchase plan on Thursday, February 26th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 9.7% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Hedge Funds Weigh In On Surgery Partners

A number of large investors have recently modified their holdings of the stock. Pentwater Capital Management LP grew its stake in shares of Surgery Partners by 66.9% during the third quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock valued at $252,777,000 after purchasing an additional 4,681,000 shares during the last quarter. UBS Group AG raised its position in Surgery Partners by 111.4% in the 4th quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock worth $120,571,000 after purchasing an additional 4,113,052 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Surgery Partners by 528.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,959,686 shares of the company’s stock worth $30,277,000 after buying an additional 1,647,714 shares in the last quarter. Glenview Capital Management LLC acquired a new position in Surgery Partners during the 2nd quarter worth $33,995,000. Finally, King Street Capital Management L.P. boosted its position in Surgery Partners by 24.5% in the 2nd quarter. King Street Capital Management L.P. now owns 6,225,000 shares of the company’s stock valued at $138,382,000 after buying an additional 1,225,000 shares during the last quarter.

Key Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Several analysts maintained buy/outperform ratings despite lowering targets, signaling continued conviction in recovery potential. Analyst Expectations For Surgery Partners’s Future
• Positive Sentiment: TD Cowen cut its price target to $20 but kept a “buy” rating, implying substantial upside from current levels if company execution improves. TD Cowen lowers PT to $20, keeps Buy
• Positive Sentiment: UBS trimmed its target to $21 while retaining a “buy” stance, another signal that analysts still see medium‑term upside despite near‑term weakness. UBS lowers PT to $21, keeps Buy
• Neutral Sentiment: Some commentary frames the current slump as a potential buying opportunity for long‑term investors, but emphasizes execution and margin recovery are key. Has Surgery Partners Slump Opened A New Opportunity For Investors?
• Negative Sentiment: Barclays cut its price target sharply to $14, signaling more conservative near‑term expectations and adding downward pressure on the stock. Barclays Lowers Surgery Partners Price Target to $14
• Negative Sentiment: Q4 results: revenue modestly beat, but EPS missed expectations and management flagged margin pressure — the core reason for the selloff and heightened execution risk. SGRY Q4 2025 Earnings Call Highlights
• Negative Sentiment: Shares hit a new 52‑week low after the earnings miss and analyst downgrades, reflecting elevated near‑term downside and investor concern about margin recovery. Surgery Partners Sets New 52-Week Low on Disappointing Earnings

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.